Manufacturing the Future: from N=1 personalised CRISPR therapy to scalable precision genomic medicine

Baby KJ’s landmark treatment, the first personalised mRNA base editing therapy for a life-threatening urea cycle disorder, demonstrated that precision gene editing can save a single life. However, the true challenge for the field is scale, transforming singular breakthroughs into solutions that can reach all who need them.

 Key learning points: 

• Learn how to overcome key manufacturing bottlenecks
• Understand how N=1 therapies can scale sustainably
• Explore real-world case studies shaping the future of CRISPR.

This webinar brings together a panel of translational experts to explore the intellectual, technical and translational journey from this N-of-1 clinical triumph to a platform capable of treating many patients. Achieving this vision requires new models of partnership, grounded in platform thinking and shared innovation.

Speakers will discuss how optimised process development, scalable manufacturing, advanced QC analytics and evolving regulatory frameworks must come together to convert bespoke interventions into reproducible, accessible and cost-effective genetic medicines.

Who should attend? This session is designed for professionals working in cell & gene therapy, biopharmaceutical manufacturing, translational research, process development, regulatory affairs and clinical development. 

If you are involved in bringing advanced therapies from concept to clinic – this webinar is for you. 

Attendees will learn how organisations are approaching the transition from personalised therapies to scalable platforms and the key challenges in enabling broader clinical uses.

Register now to access this webinar on demand!